risk ratio

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Admission adverse event adverse events all-cause mortality antiparasitic Antiviral approach ARMS Asymptomatic certainty certainty of evidence citation classification Clinical improvement clinical trial Cochrane COVID-19 Study Register coronavirus coronavirus disease COVID-19 COVID-19 diagnosis COVID-19 symptoms COVID-19 treatment Data collection database death discharged disease disease severity double-blind duration of symptom early stage early stages Efficacy Efficacy and safety eligible Evidence excluded for inclusion GRADE hospital identify in vitro include increase index Infection infection with SARS-CoV-2 inhibit inhibitory effect initial symptom Inpatient Inpatients Intervention Invasive mechanical ventilation investigated Ivermectin life mean difference Mental Meta-analysis Mild Moderate COVID-19 moderate-to-severe COVID-19 molecular hypothesis Mortality no effect non-randomized ongoing trial ongoing trials Open-label outcome Outpatient outpatients participant Participants people with COVID-19 physical Placebo placebo-controlled Postexposure Prophylaxis Prevent Quality of life question Randomized controlled trial Randomized controlled trials RCT RCTs receiving reduce Registered Replication Reporting request Research resolved risk Risk of bias risk ratio RoB 2 SARS-CoV-2 SARS-COV-2 infection Science Citation Index searched Selection Serious Adverse Event Serious Adverse Events Seven severe acute respiratory syndrome Coronavirus Standard of care treat treated treating COVID-19 Treatment Trial trials viral clearance virus Web of Science WHO WHO guideline worsening
[DOI] 10.1002/14651858.CD015017.pub3 PMC 바로가기 [Article Type] Review